Article
Cell Biology
Nafiseh Maghsoodi, Mohammadrasul Zareinejad, Ali Golestan, Elham Mahmoudi Maymand, Amin Ramezani
Summary: This study aimed to produce and evaluate a novel αCD8/CD19 BiTE protein with direct targeting capability on CD8+ T-cells. The results showed that the recombinant αCD8/CD19 protein exhibited significant granzyme B production, cytotoxic activity, and proliferation potential in the presence of IL-2 and tumor target cells.
CELLULAR IMMUNOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Haibo Zhu, Haobin Deng, Juan Mu, Cuicui Lyu, Yanyu Jiang, Qi Deng
Summary: The anti-CD22-CAR T cell salvage therapy showed higher efficacy in R/R DLBCL patients compared to R/R B-ALL patients who had failed anti-CD19-CAR T cell therapy before. Further studies with larger sample sizes are needed for confirmation.
ONCOTARGETS AND THERAPY
(2021)
Review
Oncology
Pier Luigi Zinzani, Giorgio Minotti
Summary: Anti-CD19 monoclonal antibodies, including bispecific T-cell engager, modified anti-CD19 with enhanced affinity, and antibody-drug conjugate, show promising results in the treatment of relapsed or refractory B-cell malignancies, offering improved outcomes for certain patients with limited therapeutic options and poor prognosis.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Review
Oncology
Xingcheng Yang, Jia Wei, Jianfeng Zhou
Summary: Anti-CD19 CAR T-cell therapy has shown outstanding efficacy in treating B-cell malignancies, but a high relapse rate still exists. Understanding the resistance mechanisms and overcoming these barriers are crucial for improving the effectiveness.
HEMATOLOGICAL ONCOLOGY
(2022)
Article
Oncology
Zhitao Ying, Ting He, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Chen Zhang, Weiping Liu, Lijuan Deng, Meng Wu, Feier Feng, Xin Leng, Tingting Du, Feifei Qi, Xuelian Hu, Yanping Ding, Xin-an Lu, Yuqin Song, Jun Zhu
Summary: CAR-T cells can proliferate in mice with or without target cells, and can persist for a long time in non-Hodgkin lymphoma patients with mild side effects that can be effectively controlled within two months.
Article
Biochemistry & Molecular Biology
Andreas Mackensen, Fabian Mueller, Dimitrios Mougiakakos, Sebastian Boeltz, Artur Wilhelm, Michael Aigner, Simon Voelkl, David Simon, Arnd Kleyer, Luis Munoz, Sascha Kretschmann, Soraya Kharboutli, Regina Gary, Hannah Reimann, Wolf Roesler, Stefan Uderhardt, Holger Bang, Martin Herrmann, Arif Buelent Ekici, Christian Buettner, Katharina Maria Habenicht, Thomas H. Winkler, Gerhard Kroenke, Georg Schett
Summary: A study of five patients with refractory systemic lupus erythematosus treated with anti-CD19 CAR T cell therapy showed remission of SLE disease in all patients after 3 months, and long-term drug-free remission was maintained during follow-up.
Article
Plant Sciences
Shi Dong, Peipei Wang, Liubo Zhang, Xiaotian Zhang, Xiaorui Li, Jiali Wang, Xinming Cui, Ting Lan, Can Gao, Yuanyuan Shi, Weijia Wang, Jianxun Wang, Miao Jiang
Summary: SLS can potentially enhance the function of anti-CD19 CAR T cells in treating B-cell lymphoma by improving their killing ability and reducing the risk associated with inflammation. The mechanism of SLS involves the apoptosis and IL-17 signaling pathways.
JOURNAL OF ETHNOPHARMACOLOGY
(2024)
Article
Immunology
Bailin He, Qiusui Mai, Yunyi Pang, Shikai Deng, Yi He, Rongtao Xue, Na Xu, Hongsheng Zhou, Xiaoli Liu, Li Xuan, Chengyao Li, Qifa Liu
Summary: CD19 CAR engineered memory-like NK cells exhibit enhanced persistence and antitumor activity against CD19(+) tumors, providing a potential approach to treat patients with relapsed or refractory B cell malignancies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Isabel Martinez-Romera, Victor Galan-Gomez, Berta Gonzalez-Martinez, Pilar Guerra Garcia, Sonsoles San Roman Pacheco, Dolores Corral Sanchez, Yasmina Mozo del Castillo, David Bueno Sanchez, Luisa Sisinni, Alba Gonzalez Guerrero, Serafin Castellano Damaso, Elena Sanchez Zapardiel, Beatriz Ruz Caracuel, Antonio Balas Perez, Antonio Perez-Martinez
Summary: The treatment targeting CD19 has achieved breakthroughs in managing and treating relapsed and refractory B-ALL. Continuous lineage chimerism analysis is suggested for patients who received anti-CD19 CAR-T cells after HSCT and achieved complete remission.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Harjeet Singh, Samer A. Srour, Denai R. Milton, Jessica McCarty, Cuiping Dai, Mahmoud R. Gaballa, Mariam Ammari, Simon Olivares, Helen Huls, Eleanor De Groot, David Marin, Demetrios Petropoulos, Amanda L. Olson, Paolo Anderlini, Jin S. Im, Issa Khouri, Chitra M. Hosing, Katayoun Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Laurence J. N. Cooper, Partow Kebriaei
Summary: CAR T-cell therapy is an effective treatment for relapsed or refractory leukemia and lymphoma. The modified SB CD19 CAR construct has shown improved efficacy and safety, with encouraging anti-tumor activity.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Qingzhu Jia, Diyuan Qin, Feng He, Qichao Xie, Zhitao Ying, Yajing Zhang, Yuqin Song, Jia-Nan Cheng, Xuejiao Zuo, Luxiang Xu, Hongliang Fang, Chunyan Hu, Lina Peng, Tao Jin, Zixiao Shi, Peter B. Alexander, Yongsheng Wang, Yarong Liu, Weidong Han, Jun Zhu, Pin Wang, Qi-Jing Li, Bo Zhu
Summary: This study identified the baseline high eosinophil count as a potential biomarker for predicting the clinical efficacy of CAR-T cell therapy in B-NHL patients. A preclinical model demonstrated that depletion of eosinophils could impair the intratumoral infiltration and antitumor efficacy of CAR-T cells.
Article
Cell Biology
Zhenyu Dai, Xuelian Hu, Xiangyin Jia, Jianwei Liu, Yongkun Yang, Panpan Niu, Guang Hu, Taochao Tan, Jianfeng Zhou
Summary: Through an optimized screening strategy, two human anti-CD19 scFv candidates were discovered in this study, showing excellent cytotoxicity in CAR-T cells and bispecific antibodies. Clone 78-BBz CAR-T cells demonstrated similar in vivo antitumor activity to FMC63-BBz CAR-T cells, indicating excellent efficacy and safety profile as a potential candidate for clinical development.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Nikolaos Ioannou, Khushi Jain, Alan G. Ramsay
Summary: Accumulating evidence suggests that IMiDs and CELMoDs have pleiotropic effects on tumor microenvironment and immune system, making them suitable for combination therapy in CLL and NHL. These drugs have shown promising clinical efficacy, opening up new directions for cancer immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biology
Zhaoqi Chen, Yan Liu, Nianci Chen, Haiyan Xing, Zheng Tian, Kejing Tang, Qing Rao, Yingxi Xu, Ying Wang, Min Wang, Jianxiang Wang
Summary: CD19 chimeric antigen receptor (CAR) T cells have shown success in acute lymphoblastic leukemia but have limited efficacy in other types of leukemia and lymphoma. This study constructed bispecific CAR-T cells targeting both CD19 and CD20 antigens, which demonstrated superior efficacy in eliminating lymphoma cells in vitro and in a mouse model. The loop2019 CAR structure showed the highest efficiency and potential for clinical treatment.
SCIENCE CHINA-LIFE SCIENCES
(2023)
Article
Biochemical Research Methods
Youming Wang, Rui Sun, Weigang Ge, Lei Xue, Qianwen Xu, Hui Xu, Sujun Li, Miaomiao Wu, Tiannan Guo, Xingbing Wang
Summary: This study investigated the potential biomarkers of cytokine release syndrome (CRS) induced by CAR-T cell therapy. APOA1 and CD163 were identified as potential biomarkers through quantitative proteomics analysis of serum samples from B-cell acute lymphoblastic leukemia (B-ALL) patients.
JOURNAL OF PROTEOME RESEARCH
(2023)
Article
Oncology
Vincent Ribrag, Jehan Dupuis, Herve Tilly, Franck Morschhauser, Fabrice Laine, Roch Houot, Corinne Haioun, Christiane Copie, Andrea Varga, John Lambert, Laurence Hatteville, Samira Ziti-Ljajic, Anne Caron, Sandrine Payrard, Bertrand Coiffier
CLINICAL CANCER RESEARCH
(2014)
Article
Endocrinology & Metabolism
Jean-Michel Itier, Gwenaelle Ret, Sandra Viale, Lindsay Sweet, Dinesh Bangari, Anne Caron, Francoise Le-Gall, Bernard Benichou, John Leonard, Jean-Francois Deleuze, Cecile Orsini
JOURNAL OF INHERITED METABOLIC DISEASE
(2014)
Article
Chemistry, Medicinal
Benoit Pasquier, Youssef El-Ahmad, Bruno Filoche-Romme, Christine Dureuil, Florence Fassy, Pierre-Yves Abecassis, Magali Mathieu, Thomas Bertrand, Tsiala Benard, Cedric Barriere, Samira El Batti, Jean-Philippe Letallec, Veronique Sonnefraud, Maurice Brollo, Laurence Delbarre, Veronique Loyau, Fabienne Pilorge, Luc Bertin, Patrick Richepin, Jerome Arigon, Jean-Robert Labrosse, Jacques Clement, Florence Durand, Romain Combet, Pierre Perraut, Vincent Leroy, Frederic Gay, Dominique Lefrancois, Francois Bretin, Jean-Pierre Marquette, Nadine Michot, Anne Caron, Christelle Castell, Laurent Schio, Gary McCort, Helene Goulaouic, Carlos Garcia-Echeverria, Baptiste Ronan
JOURNAL OF MEDICINAL CHEMISTRY
(2015)
Article
Biotechnology & Applied Microbiology
Iris Baumgartner, Nicolas Chronos, Anthony Comerota, Timothy Henry, Jean-Paul Pasquet, Francois Finiels, Anne Caron, Jean-Francois Dedieu, Richard Pilsudski, Pia Delaere
Article
Oncology
Celine Nicolazzi, Anne Caron, Alexia Tellier, Marc Trombe, Jan Pinkas, Gillian Payne, Chantal Carrez, Stephane Guerif, Marie Maguin, Raffaele Baffa, Matteo Fassan, Julien Adam, Lydie Mangatal-Wade, Veronique Blanc
MOLECULAR CANCER THERAPEUTICS
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Laurent Besret, Sebastien d'Heilly, Cathy Aubert, Guillaume Bluet, Florence Gruss-Leleu, Francoise Le-Gall, Anne Caron, Laurent Andrieu, Sylvie Vincent, Maysoun Shomali, Monsif Bouaboula, Carole Voland, Jeffrey Ming, Sebastien Roy, Srinivas Rao, Chantal Carrez, Erwan Jouannot
Article
Biotechnology & Applied Microbiology
A Caron, S Michelet, A Caron, S Sordello, MA Ivanov, P Delaère, D Branellec, B Schwartz, F Emmanuel
JOURNAL OF GENE MEDICINE
(2004)
Article
Biotechnology & Applied Microbiology
R Darteil, MP Wang, M Latta-Mahieu, A Caron, A Mahfoudi, B Staels, V Thuillier